What is TENX's current stock price?

TENX (Tenax Therapeutics, Inc.) is currently trading at $11.98 with a market cap of $206.0M.

What sector is Tenax Therapeutics, Inc. in?

Tenax Therapeutics, Inc. (TENX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is TENX a good stock to buy?

Analysts have a Buy consensus on TENX with a price target of $25.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

TENX Tenax Therapeutics, Inc.

Healthcare

$11.98-1.24%ClosedMarket Cap: $206.0M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.72

P/S

0.00

EV/EBITDA

-1.49

DCF Value

$2.35

FCF Yield

-18.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-56.3%

ROA

-47.0%

ROIC

-53.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-15.7M	$—
Q4 null	$0.00	$-15.5M	$—
FY null	$0.00	$-52.6M	$—
Q3 null	$0.00	$-15.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$25.00

Target (Median)

$25.00

Target Range

$25.00 - $25.00

1 Strong Buy6 Buy0 Hold0 Sell0 Strong Sell

GuggenheimBuy

2026-03-16

GuggenheimBuy

2025-12-17

GuggenheimBuy

2025-08-14

Trading Activity

Insider Trades

View All

STAAB THOMAS R IIofficer: Chief Financial Officer

SellWed May 13

STAAB THOMAS R IIofficer: Chief Financial Officer

SellWed May 13

STAAB THOMAS R IIofficer: Chief Financial Officer

SellWed May 13

MCGAULEY THOMASofficer: Interim CFO

SellTue Feb 03

Rich Stuartdirector, officer: Chief Medical Officer

SellTue Jan 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.00

Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.

Peers